Effect of Dapagliflozin on LV Remodeling Post AMI

Sponsor
Instituto Mexicano del Seguro Social
Study ID
NCT04783870
Phase
PHASE4
Status
Unknown

Conditions

  • Myocardial Infarction

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    Dapagliflozin 10 mg PO QD
  • Placebo — DRUG
    Placebo

Study Details

The overall hypothesis of the study is that Dapagliflozin will reduce left ventricular remodeling in patients who have had a myocardial infarction.

Key Dates

Start date
Mar 3, 2021
Status verified
Mar 2021
Primary completion
Dec 31, 2023
Completion
Dec 31, 2024

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin
    Dapagliflozin 10 mg PO QD
  • Placebo Comparator: Control
    Placebo PO QD

Primary Outcome Measure

Left ventricular remodeling [ Time Frame: 6 months ]

Central Contacts

Related Studies